Louise Mawer

GXP Auditor and Trainer
Mirabilitas Ltd, UK
Louise is a quality assurance auditor and trainer with extensive experience in Good Clinical Practice (GCP), Good Laboratory Practice (GLP) and, more recently, Good Pharmacovigilance Practice (GVP). She studied at Leicester Polytechnic (Science of Medicinal & Cosmetic products) and The Open University (BSc Honours).
Working initially in inhalation formulations research and development, Louise moved into Quality Assurance in 1995, where she was employed by a UK Phase I unit with responsibility for overseeing GCP Study compliance.
She left Leicester to move to Harrogate, North Yorkshire, and a large Contract Research Organisation, working in the field of GLP. Moving again to a Biologics company combining both her GCP and GLP Quality Assurance activities.
Following 10 years as an auditor, Louise joined the UK Medicines and Healthcare Products Regulatory Agency (MHRA), as a GCP Inspector where she cross-trained as a GLP Monitoring Authority (GLPMA) Inspector.
An active participant at the European Medicines Agency (EMA) GCP Inspectors Working Group, Louise supported the development of guidance on risk-adapted clinical trial methodologies, bioequivalence and clinical laboratory inspections, and GCP for Advanced Therapy Medicinal Products. Louise also participated in joint working with US FDA Investigators for GCP and contributed to Clinical Trial Transformation Initiative meetings.
She currently provides Quality Assurance and training support to those involved in pharmaceutical development, including pharmaceutical companies, biotech companies and those in the non commercial sector. She is the Chair of the Quality Working Party for the European Forum for GCP (EFGCP) and is a member of The Research Quality Association Research Practice Group and Northern Regional Forum.

Events/Masterclasses Louise Mawer is currently speaking at

Pharma

Toxicology, ADME & Early Drug Development Plan
15 – 17 October 2024
Online Live Stream | 14:00 CEST – 18:00 CEST
Building an Integrated Safety Testing Strategy based on ADME and Toxicology. The purpose of this Toxicology, ADME & Early Drug Development Plan is to understand the concept of a combined ADME-Toxicology approach.

Pharma

Good Laboratory Practice & Good Clinical Laboratory Practice
26 - 27 September 2024
Online Live Stream | 9:30 CEST – 17:30 CEST
This two-day course with workshop and case examples is designed for Managers and Sponsors of GLP and/or GCP Studies to develop a working knowledge of GLP and GCP requirements to support implementation of the Quality Management System in a GLP and/or GCP setting.

Are you interested in a custom-made event with this trainer?

Contact us to Request more information about your custom-made Corporate Learning program.

REQUEST MORE INFORMATION

Louise Mawer
GXP Auditor and Trainer
Mirabilitas Ltd, UK
Louise is a quality assurance auditor and trainer with extensive experience in Good Clinical Practice (GCP), Good Laboratory Practice (GLP) and, more recently, Good Pharmacovigilance Practice (GVP). She studied at Leicester Polytechnic (Science of Medicinal & Cosmetic products) and The Open University (BSc Honours).
Working initially in inhalation formulations research and development, Louise moved into Quality Assurance in 1995, where she was employed by a UK Phase I unit with responsibility for overseeing GCP Study compliance.
She left Leicester to move to Harrogate, North Yorkshire, and a large Contract Research Organisation, working in the field of GLP. Moving again to a Biologics company combining both her GCP and GLP Quality Assurance activities.
Following 10 years as an auditor, Louise joined the UK Medicines and Healthcare Products Regulatory Agency (MHRA), as a GCP Inspector where she cross-trained as a GLP Monitoring Authority (GLPMA) Inspector.
An active participant at the European Medicines Agency (EMA) GCP Inspectors Working Group, Louise supported the development of guidance on risk-adapted clinical trial methodologies, bioequivalence and clinical laboratory inspections, and GCP for Advanced Therapy Medicinal Products. Louise also participated in joint working with US FDA Investigators for GCP and contributed to Clinical Trial Transformation Initiative meetings.
She currently provides Quality Assurance and training support to those involved in pharmaceutical development, including pharmaceutical companies, biotech companies and those in the non commercial sector. She is the Chair of the Quality Working Party for the European Forum for GCP (EFGCP) and is a member of The Research Quality Association Research Practice Group and Northern Regional Forum.
Louise Mawer
Description